Click here to get full coverage on With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business - simplywall.st

With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business  simplywall.st

With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business - simplywall.st

Click here to get full coverage on Key resistance and support levels for AXGN - July 2025 Levels & Real-Time Chart Breakout Alerts - newser.com

Key resistance and support levels for AXGN - July 2025 Levels & Real-Time Chart Breakout Alerts  newser.com

Key resistance and support levels for AXGN - July 2025 Levels & Real-Time Chart Breakout Alerts - newser.com

Click here to get full coverage on Insider Sell Alert: Burke William P. Mr. Sells 1,457 Shares of A - GuruFocus

Insider Sell Alert: Burke William P. Mr. Sells 1,457 Shares of A  GuruFocus

Insider Sell Alert: Burke William P. Mr. Sells 1,457 Shares of A - GuruFocus

Click here to get full coverage on What risks investors should watch in AXGN stock - 2025 Market WrapUp & Weekly Top Gainers Trade List - nchmf.gov.vn

What risks investors should watch in AXGN stock - 2025 Market WrapUp & Weekly Top Gainers Trade List  nchmf.gov.vn

What risks investors should watch in AXGN stock - 2025 Market WrapUp & Weekly Top Gainers Trade List - nchmf.gov.vn

Click here to get full coverage on AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?  Yahoo Finance

AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Click here to get full coverage on Insider Sale: Director at $AXGN Sells 14,571 Shares - Quiver Quantitative

Insider Sale: Director at $AXGN Sells 14,571 Shares  Quiver Quantitative

Insider Sale: Director at $AXGN Sells 14,571 Shares - Quiver Quantitative

Click here to get full coverage on AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm  Business Wire

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Click here to get full coverage on AxoGen, Inc. (AXGN) Stock Analysis: Exploring A 47.85% Upside Potential - DirectorsTalk Interviews

AxoGen, Inc. (AXGN) Stock Analysis: Exploring A 47.85% Upside Potential  DirectorsTalk Interviews

AxoGen, Inc. (AXGN) Stock Analysis: Exploring A 47.85% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on HC Wainwright & Co. Initiates Coverage of Axogen (AXGN) with Buy Recommendation - Nasdaq

HC Wainwright & Co. Initiates Coverage of Axogen (AXGN) with Buy Recommendation  Nasdaq

HC Wainwright & Co. Initiates Coverage of Axogen (AXGN) with Buy Recommendation - Nasdaq

Click here to get full coverage on Oct 29: Axogen to Report Q3 Results and Host Investor Webcast; replay & slides available on site - Stock Titan

Oct 29: Axogen to Report Q3 Results and Host Investor Webcast; replay & slides available on site  Stock Titan

Oct 29: Axogen to Report Q3 Results and Host Investor Webcast; replay & slides available on site - Stock Titan

Click here to get full coverage on Can AXGN recover in the next quarter - 2025 Dividend Review & Stepwise Trade Execution Plans - newser.com

Can AXGN recover in the next quarter - 2025 Dividend Review & Stepwise Trade Execution Plans  newser.com

Can AXGN recover in the next quarter - 2025 Dividend Review & Stepwise Trade Execution Plans - newser.com

Click here to get full coverage on What risks investors should watch in AXGN stock - Weekly Trade Summary & Long Hold Capital Preservation Tips - nchmf.gov.vn

What risks investors should watch in AXGN stock - Weekly Trade Summary & Long Hold Capital Preservation Tips  nchmf.gov.vn

What risks investors should watch in AXGN stock - Weekly Trade Summary & Long Hold Capital Preservation Tips - nchmf.gov.vn

Click here to get full coverage on Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin - Yahoo Finance

Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin  Yahoo Finance

Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $AXGN Given 'Buy' Rating - Quiver Quantitative

New Analyst Forecast: $AXGN Given 'Buy' Rating  Quiver Quantitative

New Analyst Forecast: $AXGN Given 'Buy' Rating - Quiver Quantitative

Click here to get full coverage on Can AXGN recover in the next quarter - 2025 Major Catalysts & Daily Volume Surge Trade Alerts - newser.com

Can AXGN recover in the next quarter - 2025 Major Catalysts & Daily Volume Surge Trade Alerts  newser.com

Can AXGN recover in the next quarter - 2025 Major Catalysts & Daily Volume Surge Trade Alerts - newser.com

Click here to get full coverage on Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect? - Yahoo Finance

Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?  Yahoo Finance

Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect? - Yahoo Finance

Click here to get full coverage on When Will Axogen, Inc. (NASDAQ:AXGN) Breakeven? - Yahoo Finance

When Will Axogen, Inc. (NASDAQ:AXGN) Breakeven?  Yahoo Finance

When Will Axogen, Inc. (NASDAQ:AXGN) Breakeven? - Yahoo Finance

Click here to get full coverage on Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - Yahoo Finance

Raymond James Slashes PT on Axogen (AXGN) to $20 From $21  Yahoo Finance

Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - Yahoo Finance

Click here to get full coverage on AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Yahoo Finance

AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Click here to get full coverage on Are Medical Stocks Lagging AxoGen (AXGN) This Year? - Yahoo Finance

Are Medical Stocks Lagging AxoGen (AXGN) This Year?  Yahoo Finance

Are Medical Stocks Lagging AxoGen (AXGN) This Year? - Yahoo Finance

Click here to get full coverage on Why AXGN stock appeals to dividend seekers - Quarterly Profit Report & Safe Capital Allocation Plans - nchmf.gov.vn

Why AXGN stock appeals to dividend seekers - Quarterly Profit Report & Safe Capital Allocation Plans  nchmf.gov.vn

Why AXGN stock appeals to dividend seekers - Quarterly Profit Report & Safe Capital Allocation Plans - nchmf.gov.vn

Click here to get full coverage on Can AXGN recover in the next quarter - Product Launch & Comprehensive Market Scan Reports - newser.com

Can AXGN recover in the next quarter - Product Launch & Comprehensive Market Scan Reports  newser.com

Can AXGN recover in the next quarter - Product Launch & Comprehensive Market Scan Reports - newser.com

Click here to get full coverage on Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... - Yahoo Finance

Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ...  Yahoo Finance

Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... - Yahoo Finance

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Is Investigating Axogen, Inc. (AXGN) And Encourages Shareholders to Connect - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Axogen, Inc. (AXGN) And Encourages Shareholders to Connect  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Axogen, Inc. (AXGN) And Encourages Shareholders to Connect - ACCESS Newswire

Click here to get full coverage on Axogen (AXGN) Q2 Revenue Jumps 18% - Nasdaq

Axogen (AXGN) Q2 Revenue Jumps 18%  Nasdaq

Axogen (AXGN) Q2 Revenue Jumps 18% - Nasdaq

Click here to get full coverage on FDA Pushes Axogen's Groundbreaking Nerve Graft Review to December Following New Manufacturing Data - Stock Titan

FDA Pushes Axogen's Groundbreaking Nerve Graft Review to December Following New Manufacturing Data  Stock Titan

FDA Pushes Axogen's Groundbreaking Nerve Graft Review to December Following New Manufacturing Data - Stock Titan

Click here to get full coverage on Insider Sale: Chief Innovation Officer of $AXGN Sells 1,137 Shares - Quiver Quantitative

Insider Sale: Chief Innovation Officer of $AXGN Sells 1,137 Shares  Quiver Quantitative

Insider Sale: Chief Innovation Officer of $AXGN Sells 1,137 Shares - Quiver Quantitative

Click here to get full coverage on AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - Nasdaq

AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates  Nasdaq

AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - Nasdaq

Click here to get full coverage on Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - Yahoo Finance

Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know  Yahoo Finance

Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 - Sahm

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025  Sahm

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 - Sahm

Click here to get full coverage on Axogen gains on report of takeover interest - Seeking Alpha

Axogen gains on report of takeover interest  Seeking Alpha

Axogen gains on report of takeover interest - Seeking Alpha

Click here to get full coverage on Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined  Seeking Alpha

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha

Click here to get full coverage on Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)? - simplywall.st

Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)?  simplywall.st

Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)? - simplywall.st

Click here to get full coverage on Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2025-08-05 - Seeking Alpha

Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2025-08-05  Seeking Alpha

Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2025-08-05 - Seeking Alpha

Click here to get full coverage on $AXGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$AXGN stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$AXGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on When Can We Expect A Profit From Axogen, Inc. (NASDAQ:AXGN)? - simplywall.st

When Can We Expect A Profit From Axogen, Inc. (NASDAQ:AXGN)?  simplywall.st

When Can We Expect A Profit From Axogen, Inc. (NASDAQ:AXGN)? - simplywall.st

Click here to get full coverage on Institutional investors in Axogen, Inc. (NASDAQ:AXGN) see US$53m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st

Institutional investors in Axogen, Inc. (NASDAQ:AXGN) see US$53m decrease in market cap last week, although long-term gains have benefitted them.  simplywall.st

Institutional investors in Axogen, Inc. (NASDAQ:AXGN) see US$53m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN - Eastern Progress

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN  Eastern Progress

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN - Eastern Progress

Click here to get full coverage on Cantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN) - The Globe and Mail

Cantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN)  The Globe and Mail

Cantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN) - The Globe and Mail

Click here to get full coverage on Axogen Showcases Nerve Repair Vision at Goldman Sachs - Yahoo Finance

Axogen Showcases Nerve Repair Vision at Goldman Sachs  Yahoo Finance

Axogen Showcases Nerve Repair Vision at Goldman Sachs - Yahoo Finance

Click here to get full coverage on Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32% - Sahm

Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%  Sahm

Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32% - Sahm

Click here to get full coverage on Axogen, Inc. to Announce 2025 Second Quarter Financial Results on August 5, 2025 | AXGN Stock News - Quiver Quantitative

Axogen, Inc. to Announce 2025 Second Quarter Financial Results on August 5, 2025 | AXGN Stock News  Quiver Quantitative

Axogen, Inc. to Announce 2025 Second Quarter Financial Results on August 5, 2025 | AXGN Stock News - Quiver Quantitative

Click here to get full coverage on AxoGen, Inc. (AXGN) Stock Analysis: Exploring A High Potential Upside Of 52.37% - DirectorsTalk Interviews

AxoGen, Inc. (AXGN) Stock Analysis: Exploring A High Potential Upside Of 52.37%  DirectorsTalk Interviews

AxoGen, Inc. (AXGN) Stock Analysis: Exploring A High Potential Upside Of 52.37% - DirectorsTalk Interviews

Click here to get full coverage on Axogen, Inc. (NASDAQ:AXGN) Is Expected To Breakeven In The Near Future - 富途牛牛

Axogen, Inc. (NASDAQ:AXGN) Is Expected To Breakeven In The Near Future  富途牛牛

Axogen, Inc. (NASDAQ:AXGN) Is Expected To Breakeven In The Near Future - 富途牛牛

Click here to get full coverage on Canaccord Genuity reiterates Buy rating on AxoGen stock, citing BLA approval potential - Investing.com

Canaccord Genuity reiterates Buy rating on AxoGen stock, citing BLA approval potential  Investing.com

Canaccord Genuity reiterates Buy rating on AxoGen stock, citing BLA approval potential - Investing.com

Click here to get full coverage on Axogen (NASDAQ:AXGN) swells 10% this week, taking three-year gains to 46% - simplywall.st

Axogen (NASDAQ:AXGN) swells 10% this week, taking three-year gains to 46%  simplywall.st

Axogen (NASDAQ:AXGN) swells 10% this week, taking three-year gains to 46% - simplywall.st

Click here to get full coverage on What technical models suggest about AXGN’s comeback - Share Buyback & AI Powered Market Entry Ideas - newser.com

What technical models suggest about AXGN’s comeback - Share Buyback & AI Powered Market Entry Ideas  newser.com

What technical models suggest about AXGN’s comeback - Share Buyback & AI Powered Market Entry Ideas - newser.com

Click here to get full coverage on Is AXGN a good long term investment - Market Capitalization Trends & Superior Capital Growth - earlytimes.in

Is AXGN a good long term investment - Market Capitalization Trends & Superior Capital Growth  earlytimes.in

Is AXGN a good long term investment - Market Capitalization Trends & Superior Capital Growth - earlytimes.in

Click here to get full coverage on Axogen, Inc. Receives FDA Extension for Avance® Nerve Graft Biologics License Application Review - Quiver Quantitative

Axogen, Inc. Receives FDA Extension for Avance® Nerve Graft Biologics License Application Review  Quiver Quantitative

Axogen, Inc. Receives FDA Extension for Avance® Nerve Graft Biologics License Application Review - Quiver Quantitative

Click here to get full coverage on Axogen (AXGN) Considers Potential Sale Amid Acquisition Interest - GuruFocus

Axogen (AXGN) Considers Potential Sale Amid Acquisition Interest  GuruFocus

Axogen (AXGN) Considers Potential Sale Amid Acquisition Interest - GuruFocus

Click here to get full coverage on AxoGen stock rating reiterated as Buy by H.C. Wainwright - Investing.com

AxoGen stock rating reiterated as Buy by H.C. Wainwright  Investing.com

AxoGen stock rating reiterated as Buy by H.C. Wainwright - Investing.com

Click here to get full coverage on Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN - The Globe and Mail

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN  The Globe and Mail

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN - The Globe and Mail

Click here to get full coverage on Axogen (AXGN) Considers Potential Sale Amid Takeover Proposal - GuruFocus

Axogen (AXGN) Considers Potential Sale Amid Takeover Proposal  GuruFocus

Axogen (AXGN) Considers Potential Sale Amid Takeover Proposal - GuruFocus

Click here to get full coverage on AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - FinancialContent

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm  FinancialContent

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - FinancialContent

Click here to get full coverage on Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted - Investor's Business Daily

Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted  Investor's Business Daily

Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted - Investor's Business Daily

Click here to get full coverage on Raymond James reiterates Outperform rating on AxoGen stock despite FDA delay - Investing.com

Raymond James reiterates Outperform rating on AxoGen stock despite FDA delay  Investing.com

Raymond James reiterates Outperform rating on AxoGen stock despite FDA delay - Investing.com

Click here to get full coverage on Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference - GlobeNewswire

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference  GlobeNewswire

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference - GlobeNewswire

Click here to get full coverage on Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛

Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $30  富途牛牛

Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Axogen, Inc. (AXGN) And Encourages Shareholders to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Axogen, Inc. (AXGN) And Encourages Shareholders to Reach Out  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Axogen, Inc. (AXGN) And Encourages Shareholders to Reach Out - ACCESS Newswire

Click here to get full coverage on Raymond James Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛

Raymond James Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $20  富途牛牛

Raymond James Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛

Click here to get full coverage on Axogen’s DeVinney sells $18,521 in shares - Investing.com

Axogen’s DeVinney sells $18,521 in shares  Investing.com

Axogen’s DeVinney sells $18,521 in shares - Investing.com

Click here to get full coverage on FDA Extends Review for AxoGen’s Avance Nerve Graft - TipRanks

FDA Extends Review for AxoGen’s Avance Nerve Graft  TipRanks

FDA Extends Review for AxoGen’s Avance Nerve Graft - TipRanks

Click here to get full coverage on Axogen Reports Strong Q2 2025 Financial Results - TipRanks

Axogen Reports Strong Q2 2025 Financial Results  TipRanks

Axogen Reports Strong Q2 2025 Financial Results - TipRanks

Click here to get full coverage on Insider Sell: Burke William P. Mr. Sells Shares of Axogen Inc (A - GuruFocus

Insider Sell: Burke William P. Mr. Sells Shares of Axogen Inc (A  GuruFocus

Insider Sell: Burke William P. Mr. Sells Shares of Axogen Inc (A - GuruFocus

Click here to get full coverage on Axogen, Inc. Reports 2025 First Quarter Financial Results - GlobeNewswire

Axogen, Inc. Reports 2025 First Quarter Financial Results  GlobeNewswire

Axogen, Inc. Reports 2025 First Quarter Financial Results - GlobeNewswire

Click here to get full coverage on Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 - Yahoo Finance

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025  Yahoo Finance

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 - Yahoo Finance

Click here to get full coverage on Why Is Axogen Stock Down 15% In Pre-Market Today? - Stocktwits

Why Is Axogen Stock Down 15% In Pre-Market Today?  Stocktwits

AXGN

Price Chart

Key Statistics

Technicals

About AXGN

Latest News

With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business - simplywall.st

Key resistance and support levels for AXGN - July 2025 Levels & Real-Time Chart Breakout Alerts - newser.com

Insider Sell Alert: Burke William P. Mr. Sells 1,457 Shares of A - GuruFocus

Advanced Charts

Top Gainers

Top Losers